(Q33344674)

26 July 2017

title

Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer (English)

1 reference

26 July 2017

1 reference

Matthew M Poggi

1

1 reference

26 July 2017

Glenn S Kroog

2

1 reference

26 July 2017

Angelo Russo

3

1 reference

26 July 2017

Christine Muir

4

1 reference

26 July 2017

John Cook

5

1 reference

26 July 2017

Judith Smith

6

1 reference

26 July 2017

James B Mitchell

7

1 reference

26 July 2017

Laurie L Herscher

8

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

International Journal of Radiation Oncology Biology Physics

26 July 2017

published in

1 reference

26 July 2017

volume

54

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

670-676

1 reference

26 July 2017

cites work

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902980-2

7 January 2021

Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902980-2

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902980-2

7 January 2021

Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902980-2

7 January 2021

Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902980-2

7 January 2021

Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902980-2

7 January 2021

Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902980-2

7 January 2021

Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902980-2

7 January 2021

Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902980-2

7 January 2021

Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902980-2

7 January 2021

10.1016/S0360-3016(02)02980-2

Identifiers

DOI

1 reference

26 July 2017

1 reference